Big data on efficacy and toxicity levels for ibrutinib in CLL
What are the challenges of allogeneic stem cell transplant in myeloma?
How to measure success in indolent disease? Endpoints, toxicity and more
Results of the Phase III DASISION trial and the future of CML treatment
Comparing continuous and fixed duration myeloma treatment with triplets and doublets